Sentinel Node Detection in Cervical Cancer
Launched by REGION SKANE · Sep 20, 2018
Trial Information
Current as of June 09, 2025
Unknown status
Keywords
ClinConnect Summary
Consecutive women with stage 1a2-2a1 cervical cancer scheduled for surgery will be approached for eligibility by defined criteria.
Sentinel nodes will be detected by a combined use of Indocyanine green and Tc99 radiocolloid ( first 75 patients) and for the continuation with either the combined use or the best performing of those tracers.
Technical success rates, adverse events (related study intervention and overall) sensitivity and negative predictive values will be estimated.
An interim analyse will be performed after 34 node positive patients based on the Fleming two stage analyse. Th...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Women of age 18 years and older at the time of informed consent.
- • Women with a pathologically proven cervical carcinoma of any histologic subtype, clinically stage 1a2- 2a1 planned for primary surgery
- • Absence of any exclusion criteria
- Exclusion Criteria:
- • Non consenting patients
- • Ongoing pregnancy
- • Inability to understand written and/or oral study information
- • Who performance status III or more
- • Previous lower limb lymphedema
- • Surgical contraindication to a laparoscopic approach or lymphadenectomy at surgeons discretion.
- • Anesthesiologic contraindication to a laparoscopic approach at the anesthetist's discretion
- • Locally advanced disease or intraabdominal/distant metastases at preoperative CT, MRI or ultrasonography
- • Radiologically suspect pelvic nodal metastatic disease according to the RECIST criteria (\>= 1 node with \>=16 mm short axis diameter)
- • Allergy to Iodine
- • Patients with a known liver disease
- • Patients with a significant bleeding disorder or mandatory antithrombotic treatment.
About Region Skane
Region Skåne is a leading healthcare authority in Sweden, dedicated to advancing medical research and improving patient care through innovative clinical trials. Committed to fostering collaboration between researchers, healthcare professionals, and patients, Region Skåne aims to enhance the understanding of various health conditions and develop effective treatment strategies. With a focus on ethical standards and patient safety, the organization plays a pivotal role in shaping the future of healthcare in the region and beyond, ensuring that clinical trials are conducted with the highest level of scientific rigor and transparency.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lund, , Sweden
Patients applied
Trial Officials
Jan Persson, ass professor
Principal Investigator
Region Skane
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials